- Enter the patient's age in years. Age points are added automatically according to the Charlson age-adjustment bands.
- The Renal Disease (2 pts) checkbox is pre-ticked because all maintenance dialysis patients have moderate-to-severe kidney disease by definition. Uncheck only if calculating CCI for a non-dialysis CKD patient without severe impairment.
- Check all 1-point and 2-point comorbidities that are present and documented in the patient's medical record.
- Select the appropriate liver disease severity (none / mild / moderate-to-severe), diabetes category (with or without end-organ damage), malignancy status (metastatic overrides the 2-pt tumor checkbox), and AIDS/HIV if present.
- Results update live: CCI comorbidity score, age-adjusted total, estimated 10-year survival, and a plain-language goals-of-care framing statement.
All computation runs in your browser; no values are stored or transmitted.
When to Use
Use the age-adjusted Charlson Comorbidity Index (CCI) when structuring a goals-of-care conversation with an elderly patient who has advanced CKD or end-stage kidney disease and is deciding whether to initiate, continue, or withdraw hemodialysis. The CCI is a validated, weighted sum of a patient's chronic illnesses that — together with age points — produces an estimate of long-term survival at a population level.
Appropriate population
Adults with CKD G4–G5 or established ESKD on maintenance dialysis, particularly patients aged 65 or older where a realistic long-term prognosis is needed to frame benefit-versus-burden decisions. Also useful for annual prognosis reassessment when new comorbidities are diagnosed, and for structuring advance care planning conversations. The renal disease item (2 points) is pre-checked because dialysis patients have, by definition, moderate-to-severe kidney disease.
When NOT to rely on it alone
The CCI is a population-level survival estimate derived from a 1980s medical cohort — it is not an individual prediction and should never be used as the sole criterion to recommend for or against dialysis. A high CCI score does not automatically mean dialysis should be withheld; it means prognosis and goals deserve an explicit, informed conversation. Always pair with frailty assessment (Clinical Frailty Scale, Fried Phenotype), functional status, the patient's values, and nephrologist judgment.
Pearls & Pitfalls
Use as a conversation anchor, not a verdict
A high CCI score opens the conversation about realistic prognosis — it does not close the conversation about dialysis. Some patients with very high scores choose to proceed with dialysis after an informed discussion; others choose conservative kidney management. The score's value is making the prognosis explicit so the patient can decide from a place of honest information rather than hope or assumption.
Pair with frailty assessment
The CCI captures comorbidity burden but not functional reserve or frailty. A patient with a moderate CCI but a Clinical Frailty Scale score of 7 (severely frail) carries a very different dialysis risk profile than a non-frail patient with the same CCI. Use the CCI alongside the CFS and Fried Phenotype (see the Frailty Assessment calculator) for the most complete picture.
Pitfalls
(1) The diabetes item is mutually exclusive — count only the higher category (with or without end-organ damage), never both. (2) Metastatic tumor (6 pts) overrides the non-metastatic solid-tumor checkbox (2 pts) — do not double-count. (3) The renal disease item should be unchecked if calculating for a non-dialysis patient without moderate-to-severe CKD. (4) The survival estimate is population-derived from a 1980s cohort; absolute percentages should be presented as "approximately" and paired with the clinician's own prognostic assessment.
Why Use It
Elderly patients starting hemodialysis carry a disproportionate comorbidity burden. Kurella Tamura et al. (NEJM 2009) showed that nursing-home patients initiating dialysis lost an average of 3.7 functional tasks within 3 months and had a median survival of 16.1 months — outcomes many patients and families had not anticipated. A structured prognosis tool like the age-adjusted CCI makes it possible to present honest, data-anchored survival estimates and to explore whether conservative kidney management (CKM) might better align with a patient's goals. The CCI has been externally validated in dialysis populations and outperforms unaided clinical impression in predicting 1- and 5-year mortality.
Charlson Comorbidity Index (Age-Adjusted)
Check each condition the patient carries and enter the patient's age. The tool computes the comorbidity score, age points, total score, and estimated 10-year survival — and generates a plain-language verdict for goals-of-care framing.
⚕ Charlson ME, Pompei P, Ales KL, MacKenzie CR. J Chronic Dis. 1987;40(5):373–83. Age adjustment: Charlson et al., J Clin Epidemiol. 1994. Estimated 10-year survival = 0.983(e^(score × 0.9)). This is a population-level prognosis estimate derived from a 1980s medical cohort, not an individual prediction. Always interpret alongside frailty, functional status, dialysis tolerance, and the patient's own goals.
Next Steps
Use the result to support — not replace — clinical judgment.
- Interpret the value against the targets shown in the calculator and the Evidence section below, in the context of the full clinical picture.
- Trend serial measurements rather than acting on a single result; confirm abnormal or unexpected values before changing management.
- Apply the relevant KDIGO / specialty-guideline threshold and document the indication.
- Escalate or refer to nephrology when results are out of range, rapidly changing, or discordant with the clinical picture — and discuss the implications with the patient.
Evidence & References
Formula & Equations
Comorbidity items and weights
| Condition | Points |
|---|---|
| Myocardial infarction | 1 |
| Congestive heart failure | 1 |
| Peripheral vascular disease | 1 |
| Cerebrovascular disease (TIA / stroke) | 1 |
| Dementia | 1 |
| Chronic pulmonary disease (COPD / asthma) | 1 |
| Connective tissue / rheumatic disease | 1 |
| Peptic ulcer disease | 1 |
| Mild liver disease (without portal hypertension) | 1 |
| Diabetes without end-organ damage | 1 |
| Hemiplegia / paraplegia | 2 |
| Moderate-to-severe renal disease / dialysis | 2 |
| Diabetes with end-organ damage (retinopathy, nephropathy, neuropathy) | 2 |
| Solid tumor (non-metastatic, diagnosed or treated within 5 years) / leukemia / lymphoma | 2 |
| Moderate-to-severe liver disease (cirrhosis with portal hypertension) | 3 |
| Metastatic solid tumor | 6 |
| AIDS / HIV (not just seropositive) | 6 |
Age adjustment (added to comorbidity score)
| Age band | Additional points |
|---|---|
| Under 50 | 0 |
| 50–59 | 1 |
| 60–69 | 2 |
| 70–79 | 3 |
| 80–89 | 4 |
| 90 and above | 5 |
Interpretation bands (age-adjusted total score)
| Age-adjusted total | Comorbidity burden | Approx. 10-yr survival | Goals-of-care framing |
|---|---|---|---|
| 0–2 | Low | > 90% | Prognosis generally favors continued dialysis if indicated; focus on quality of life and vascular risk |
| 3–4 | Moderate | 53–77% | Competing mortality risks are meaningful; frame an honest benefit-versus-burden conversation |
| 5–6 | High | 21–53% | High competing mortality; explicitly weigh dialysis burden against conservative kidney management |
| ≥ 7 | Very high | < 21% | Very high 1-year mortality; structured advance-care planning and CKM should be discussed as a genuine alternative |
Survival formula: 10-year survival (%) = 0.983^(e^(score × 0.9)) × 100. Derived from Charlson et al., J Clin Epidemiol. 1994. Validation in hemodialysis cohorts confirms predictive validity, though absolute survival percentages reflect historical cohorts and should be interpreted as relative risk estimates rather than precise predictions.
Evidence & References
The Charlson Comorbidity Index was originally derived and validated in a 1980s hospitalized medical cohort and has since been validated across multiple dialysis populations worldwide. The age-adjustment was published by Charlson et al. in 1994 and is the standard applied in nephrology studies. KDIGO's 2024 CKD guideline explicitly recognizes the CCI as a useful prognostic tool to support conservative kidney management discussions. The survival formula used here (0.983^(e^(CCI × 0.9))) is the standard published derivation.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
- Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251.
- Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS, McCulloch CE. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med. 2009;361(16):1539–1547.
- Al-Muhaiteeb A. Conservative kidney management in elderly patients with advanced CKD: an emerging paradigm. Kidney360. 2025 (in press).
- KDIGO. Clinical Practice Guideline for CKD Evaluation and Management (2024). Kidney International, 2024.
